BioStock: 100 days as Sensidose's Deputy CEO

The pharmaceutical company Sensidose has developed and markets a method for individualized treatment of Parkinson's disease in the advanced phase, the so-called wearing off phase or fluctuation phase. In November 2022, Philip Slätis took over as Deputy CEO and COO to accelerate the company’s business development and continued international expansion. 100 days into his new role as Sensidose's Deputy CEO, BioStock took the opportunity to feel Slätis' pulse and hear more about the company's growth plans.

Read the interview with Sensidose's Deputy CEO at biostock.se:

https://www.biostock.se/en/2023/02/sensidoses-deputy-ceo-on-his-100-days/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se